• By Deanna Kamienski, Beth Allan, Amanda Micklus, Steven Muntner, and Maureen Riordan
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2014.
CardioDx closes $35mm late-stage round
CardioDx Inc. (cardiovascular diagnostics) raised $35mm in a late-stage financing from Alberta Investment Management and returning shareholders. The proceeds...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
